MAB Discovery GmbH
↗Polling, Germany
MAB Discovery is a German biotechnology company specializing in the discovery and development of high-quality, functional monoclonal antibodies. Founded in 2010, the company utilizes a proprietary rabbit-based antibody discovery platform to generate antibodies against challenging targets, including GPCRs and ion channels.
In 2019, MAB Discovery sold its operational antibody generation unit and laboratory facilities in Munich to BioNTech. Following this transaction, the company shifted its focus to developing its own proprietary preclinical pipeline and collaborating with external partners. Dr. Fischer also founded IcanoMAB as a spin-off to further advance clinical-stage assets.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2010
Ownership:private
Status:operating
FUNDING
Stage:Private
Investors:PPD
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical/IND-enabling
Modalities:mAb
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:IcanoMAB
Key Partnerships:BioNTech (acquired antibody unit), Sanofi, Genmab, Synthon, Cullinan Oncology
COMPETITION
Position:Niche Player
Competitors:Synthego, Sutro Biopharma, Avidity Biosciences
LEADERSHIP
Key Executives:
Stephan Fischer - CEO
Scientific Founders:Stephan Fischer
LINKS
Website:mabdiscovery.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of MAB Discovery GmbH and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with MAB Discovery GmbH. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.